Logo

AbbVie Inc.

ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat a… read more

Healthcare

Drug Manufacturers—General

12 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$208.36

Price

+0.39%

$0.81

Market Cap

$368.080b

Large

Price/Earnings

98.8x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

+14.5%

EBITDA Margin

+6.1%

Net Profit Margin

+9.1%

Free Cash Flow Margin
Revenue

$58.328b

+3.5%

1y CAGR

+0.3%

3y CAGR

+1.0%

5y CAGR
Earnings

$3.769b

-11.9%

1y CAGR

-27.6%

3y CAGR

-20.1%

5y CAGR
EPS

$2.11

-11.7%

1y CAGR

-27.6%

3y CAGR

-20.0%

5y CAGR
Book Value

$1.462b

$136.165b

Assets

$134.703b

Liabilities

$69.889b

Debt
Debt to Assets

51.3%

5.8x

Debt to EBITDA
Free Cash Flow

$15.385b

-13.7%

1y CAGR

-14.0%

3y CAGR

-7.9%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases